Loading data for DSGN — first visit, this takes a few seconds.
Design Therapeutics, Inc. (DSGN)
NasdaqGS: DSGN
· Real-Time Price · USD
14.58
-0.44 (-2.93%)
At close: Sep 10, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Design Therapeutics, Inc. (DSGN) Stock Price, Analysis & Data
No data available
| Bid | 10.65 |
| Market Cap | 926M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.8M |
| 1.66 | |
| -1.18 | |
| n/a | |
| -9.29 | |
| P/B (ttm) | 4.59 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 5, 2026 |
| Ask | 18.75 |
| Volume | 165,166 |
| Avg. Volume (20D) | 691,806 |
| Open | 14.81 |
| Previous Close | 15.02 |
| Day's Range | 14.51 - 15.00 |
| 52-Week Range | 5.28 - 17.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DSGN
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedrei...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2021
Employees 55
Stock Exchange NasdaqGS
Ticker Symbol DSGN
Website https://www.designtx.com
Financial Performance
In 2025, Design Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -69.79M, an increase of 40.74%.
Financial StatementsEarnings Surprise
Design Therapeutics has released their quarterly earnings on Aug 3, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.32 exceeds estimates by 0.02, with 5.88% YoY growth.
Design Therapeutics, Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2